These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35800737)

  • 1. Lung cavitation in patients with anaplastic thyroid cancer treated with lenvatinib.
    Murayama D; Yamamoto Y; Matsui A; Yasukawa M; Okamoto S; Toda S; Iwasaki H
    Gland Surg; 2022 Jun; 11(6):963-969. PubMed ID: 35800737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
    Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
    [No Abstract]   [Full Text] [Related]  

  • 4. Bilateral pneumothorax in a patient with anaplastic thyroid carcinoma and lung metastasis during lenvatinib therapy: a case report.
    Lee HN; Chung WS; Jang HJ; Jee S; Tae K
    Gland Surg; 2020 Oct; 9(5):1579-1583. PubMed ID: 33224834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
    Sparano C; Godbert Y; Attard M; Do Cao C; Zerdoud S; Roudaut N; Joly C; Berdelou A; Hadoux J; Lamartina L; Schlumberger M; Leboulleux S
    Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib.
    Fukuda N; Toda K; Fujiwara YU; Wang X; Ohmoto A; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Mitani H; Takahashi S
    In Vivo; 2020; 34(5):2859-2864. PubMed ID: 32871825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer.
    Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):649-654. PubMed ID: 30051190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.
    Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
    Eur J Clin Pharmacol; 2020 May; 76(5):703-709. PubMed ID: 32034430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer.
    Iwasaki H; Toda S; Suganuma N; Murayama D; Nakayama H; Masudo K
    Mol Clin Oncol; 2020 Feb; 12(2):138-143. PubMed ID: 31929884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
    Tohyama O; Matsui J; Kodama K; Hata-Sugi N; Kimura T; Okamoto K; Minoshima Y; Iwata M; Funahashi Y
    J Thyroid Res; 2014; 2014():638747. PubMed ID: 25295214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib for Anaplastic Thyroid Cancer.
    Tahara M; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Sasaki T; Suzuki T; Fujino K; Dutcus CE; Takahashi S
    Front Oncol; 2017; 7():25. PubMed ID: 28299283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report.
    Yamazaki H; Masudo K; Kanada S; Inayama Y; Hayashi H; Fujii Y; Rino Y
    Surg Case Rep; 2023 Mar; 9(1):38. PubMed ID: 36920674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study.
    Iwasaki H; Yamazaki H; Takasaki H; Suganuma N; Nakayama H; Toda S; Masudo K
    Oncol Lett; 2018 Dec; 16(6):7271-7277. PubMed ID: 30546466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer.
    Iwasaki H; Toda S; Takahashi A; Masudo K
    Oncol Lett; 2023 Sep; 26(3):416. PubMed ID: 37614659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction.
    Koyama S; Miyake N; Fujiwara K; Morisaki T; Fukuhara T; Kitano H; Takeuchi H
    Eur Thyroid J; 2018 Jun; 7(3):139-144. PubMed ID: 30023346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer.
    Su X; Liu J; Zhang H; Gu Q; Zhou X; Ji M; Yao D
    Onco Targets Ther; 2020; 13():11183-11192. PubMed ID: 33173310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma.
    Yamazaki H; Iwasaki H; Suganuma N; Toda S; Masudo K; Nakayama H; Rino Y; Masuda M
    Gland Surg; 2021 Mar; 10(3):852-860. PubMed ID: 33842230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.